Skip to main content

Table 2 Acceptability ratings for aspects of the BPaL (Nix) regimen and the individualized treatment regimena

From: Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

 

Overall (N = 182)

Indonesia

Kyrgyzstan

Nigeria

ITR

BPaL

ITR

BPaL

ITR

BPaL

ITR

BPaL

Baseline assessment and monitoring of treatment efficacy

Total

144

144

46

45

51

50

47

49

Acceptable

106 (74%)

127 (88%)

35 (76%)

38 (84%)

43 (84%)

47 (94%)

28 (60%)

42 (86%)

Neutral

26 (18%)

14 (10%)

7 (15%)

7 (16%)

6 (12%)

2 (4%)

13 (28%)

5 (10%)

Unacceptable

12 (8%)

3 (2%)

4 (9%)

0 (0%)

2 (4%)

1 (2%)

6 (13%)

2 (4%)

Treatment safety monitoring

Total

141

140

44

43

52

52

45

45

Acceptable

108 (77%)

115 (84%)

39 (89%)

31 (72%)

42 (81%)

45 (87%)

27 (60%)

39 (87%)

Neutral

19 (14%)

21 (15%)

2 (5%)

9 (21%)

5 (10%)

7 (14%)

12 (27%)

5 (11%)

Unacceptable

14 (10%)

4 (3%)

3 (7%)

3 (7%)

5 (10%)

0 (0%)

6 (13%)

1 (2%)

Patient friendliness

Total

136

133

43

43

39

39

54

51

Acceptable

61 (45%)

124 (93%)

20 (47%)

37 (86%)

23 (59%)

37 (95%)

18 (33%)

50 (98%)

Neutral

33 (24%)

6 (5%)

11 (26%)

5 (12%)

9 (23%)

1 (3%)

13 (24%)

0 (0%)

Unacceptable

42 (31%)

3 (2%)

12 (28%)

1 (2%)

7 (18%)

1 (3%)

23 (43%)

1 (2%)

Programmatic aspects

Total

141

132

44

42

41

41

56

53

Acceptable

85 (60%)

110 (83%)

30 (68%)

29 (69%)

28 (68%)

33 (89%)

27 (48%)

48 (91%)

Neutral

32 (23%)

19 (14%)

8 (18%)

11 (26%)

10 (24%)

3 (8%)

14 (25%)

5 (9%)

Unacceptable

24 (17%)

3 (2%)

6 (14%)

2 (5%)

3 (7%)

1 (3%)

15 (27%)

0 (0%)

Patient support

Total

146

144

41

41

48

48

57

54

Acceptable

100 (69%)

122 (85%)

29 (71%)

33 (81%)

34 (71%)

45 (92%)

37 (65%)

44 (82%)

Neutral

27 (19%)

19 (13%)

9 (22%)

8 (20%)

6 (13%)

3 (6%)

12 (21%)

8 (15%)

Unacceptable

19 (13%)

3 (2%)

3 (7%)

0 (0%)

8 (17%)

1 (2%)

8 (14%)

2 (4%)

Human resources

Total

153

153

42

42

49

51

62

60

Acceptable

90 (59%)

121 (79%)

29 (69%)

27 (64%)

29 (59%)

46 (90%)

32 (52%)

48 (80%)

Neutral

43 (28%)

26 (17%)

9 (21%)

13 (31%)

14 (29%)

4 (8%)

20 (32%)

9 (15%)

Unacceptable

20 (13%)

6 (4%)

4 (10%)

2 (5%)

6 (12%)

1 (2%)

10 (16%)

3 (5%)

PSCM

Total

79

74

25

25

28

26

26

24

Acceptable

53 (67%)

59 (80%)

18 (72%)

14 (56%)

20 (71%)

23 (92%)

15 (58%)

22 (92%)

Neutral

14 (18%)

13 (18%)

4 (16%)

10 (40%)

5 (18%)

2 (8%)

5 (19%)

1 (4%)

Unacceptable

12 (15%)

2 (3%)

3 (12%)

1 (4%)

3 (11%)

1 (0%)

6 (23%)

1 (4%)

  1. a Since certain topics of the acceptability matrix were only collected for certain stakeholder groups and optional or not required for others (Table 1), only missing values for “mandatory” topics for the respective stakeholder were considered “true missing” values. Answers were excluded if the question was not a topic for the respective stakeholder
  2. BPaL bedaquiline & pretomanid & linezolid, ITR Individualized Treatment Regimen, PSCM procurement and supply chain management